The Europe Vaccine Adjuvants Market would witness market growth of 3.6% CAGR during the forecast period (2023-2030).
Increasing biotechnology advancement, a rising prevalence of infectious diseases among the population, government funding, and rising R&D expenditures are the primary factors influencing the expansion of the market. Vaccine adjuvant development is being propelled and fueled by advancements in innate immunity, which have made substantial strides over the last twenty years due to identifying an incalculable number of innate immune receptors and pathways. Antibodies that detect pathogen-associated molecular patterns (PAMPs), host-derived, danger-associated molecular patterns (DAMPs), and molecules involved in the signaling pathways utilized by these receptors provide an abundance of potential targets for agonists.
These agonists allow for an unprecedented level of control over innate immune responses. In addition to selecting immunostimulatory or specific adjuvant combinations, targeted modulation of immune responses can be accomplished by formulating and methodically modifying the chemical composition of immunostimulatory molecules. Utilizing high-throughput and medium-throughput screening techniques has significantly expedited the discovery of novel adjuvants with promising immunostimulatory properties. Nevertheless, despite the advancements achieved via methodical screening campaigns to discover novel adjuvants, the procedure still needs to be developed further.
According to the International Trade Administration (ITA), with a size of $12.3 billion in 2020, the Italian biotechnology sector is experiencing growth. The industry with the most significant number of firms, 376 out of 777 or 48%, is red biotechnology (life sciences). The nation has 100 public research institutes and university laboratories, 47 scientific and research hospitals, and 200 innovative startups. With Italy's contributions to biotech innovation in adjuvant technology, there's potential for the expansion of the market. Consequently, the rapid advancements in the health and biotechnology industries are propelling the growth of the market in the region.
The Germany market dominated the Europe Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $129.6 Million by 2030. The UK market is exhibiting a CAGR of 2.6% during (2023 - 2030). Additionally, The France market would experience a CAGR of 4.4% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Increasing biotechnology advancement, a rising prevalence of infectious diseases among the population, government funding, and rising R&D expenditures are the primary factors influencing the expansion of the market. Vaccine adjuvant development is being propelled and fueled by advancements in innate immunity, which have made substantial strides over the last twenty years due to identifying an incalculable number of innate immune receptors and pathways. Antibodies that detect pathogen-associated molecular patterns (PAMPs), host-derived, danger-associated molecular patterns (DAMPs), and molecules involved in the signaling pathways utilized by these receptors provide an abundance of potential targets for agonists.
These agonists allow for an unprecedented level of control over innate immune responses. In addition to selecting immunostimulatory or specific adjuvant combinations, targeted modulation of immune responses can be accomplished by formulating and methodically modifying the chemical composition of immunostimulatory molecules. Utilizing high-throughput and medium-throughput screening techniques has significantly expedited the discovery of novel adjuvants with promising immunostimulatory properties. Nevertheless, despite the advancements achieved via methodical screening campaigns to discover novel adjuvants, the procedure still needs to be developed further.
According to the International Trade Administration (ITA), with a size of $12.3 billion in 2020, the Italian biotechnology sector is experiencing growth. The industry with the most significant number of firms, 376 out of 777 or 48%, is red biotechnology (life sciences). The nation has 100 public research institutes and university laboratories, 47 scientific and research hospitals, and 200 innovative startups. With Italy's contributions to biotech innovation in adjuvant technology, there's potential for the expansion of the market. Consequently, the rapid advancements in the health and biotechnology industries are propelling the growth of the market in the region.
The Germany market dominated the Europe Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $129.6 Million by 2030. The UK market is exhibiting a CAGR of 2.6% during (2023 - 2030). Additionally, The France market would experience a CAGR of 4.4% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Scope of the Study
Market Segments Covered in the Report:
By Type
- Particulate
- Adjuvant Emulsion
- Pathogen
- Combination
- Others
By Administration
- Intramuscular
- Intranasal
- Oral
- Intradermal
- Others
By Application
- Infectious Diseases
- Cancer
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Vaccine Adjuvants Market, by Type
Chapter 6. Europe Vaccine Adjuvants Market, by Administration
Chapter 7. Europe Vaccine Adjuvants Market, by Application
Chapter 8. Europe Vaccine Adjuvants Market, by Country
Chapter 9. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Methodology
LOADING...
